지속형 피하 인슐린 주입 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 환자 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Continuous Subcutaneous Insulin Infusion Market Growth & Trends:

The global continuous subcutaneous insulin infusion market size is anticipated to reach USD 1.14 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 9.0% from 2025 to 2030. The key drivers of the market include increasing number of diabetes population coupled with technological advancement in the field of diabetes care.

According to International Diabetes Federation (IDF), the total number of diabetic population is expected to grow by 51.0% from 463.0 million in 2019 to 700.0 million in 2045. Rising health expenditure and growing awareness about preventive care is expected to boost market growth. According to the IDF, the estimated total global health expenditure to diabetes was USD 760.0 billion and is projected to grow to USD 845.0 billion by 2045. Furthermore, rising government initiatives to spread the awareness about diabetes is propelling the adoption of advanced diabetes management devices. Australian government launched Australian National Diabetes Strategy 2016 to 2020. The strategy aims to trace country's national response to this epidemic and inform how existing limited healthcare can be better targeted across all level of government.

Increasing number of product launches and advent of artificial intelligence in the market is boosting the growth. Many startups are transforming CSII therapy. These companies are taking initiatives to lessen the burden of diabetes with help of AI technology. They are leveraging technological advancement to improve market solutions like integrated insulin pumps, non-invasive insulin delivery systems, and closed-loop artificial pancreases.

Continuous Subcutaneous Insulin Infusion Market Report Highlights:

• The patch pump segment is expected to grow at the fastest CAGR of 10.2% over the forecast period, owing to the increasing demand for convenient, customizable insulin delivery solutions that cater to people with higher insulin requirements, such as those with Type 2 diabetes.
• The diabetes type 1 segment held the largest market share of 82.1% in 2024, which can be attributed to the growing global prevalence of diabetes type 1, necessitating efficient and continuous insulin delivery solutions for better blood sugar management.
• The diabetes type 2 segment is expected to grow at the fastest CAGR of 10.0% over the forecast period.
• North America continuous subcutaneous insulin infusion market held the largest share of 39.2% in 2024, which can be attributed to the approval of advanced insulin pumps that feature meal detection technology and automatic insulin corrections, enhancing blood sugar control and making diabetes management more convenient for patients.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Patient Type
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Continuous Subcutaneous Insulin Infusion Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Continuous Subcutaneous Insulin Infusion Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Patch Pumps
  • 4.4.1. Patch pumps market, 2018 - 2030 (USD Million)
  • 4.4.2. Basal
    • 4.4.2.1. Basal market, 2018 - 2030 (USD Million)
  • 4.4.3. Bolus
    • 4.4.3.1. Bolus market, 2018 - 2030 (USD Million)
  • 4.4.4. Basal and Bolus
    • 4.4.4.1. Basal and bolus market, 2018 - 2030 (USD Million)
• 4.5. Tethered Pumps
  • 4.5.1. Tethered pumps market, 2018 - 2030 (USD Million)
  • 4.5.2. Insulin Reservoir or Cartridges
    • 4.5.2.1. Insulin reservoir or cartridges market, 2018 - 2030 (USD Million)
  • 4.5.3. Insulin Set Insertion Devices
    • 4.5.3.1. Insulin set insertion devices market, 2018 - 2030 (USD Million)
  • 4.5.4. Battery
    • 4.5.4.1. Battery market, 2018 - 2030 (USD Million)

Chapter 5. Continuous Subcutaneous Insulin Infusion Market: Patient Type Business Analysis

• 5.1. Patient Type Market Share, 2024 & 2030
• 5.2. Patient Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Patient Type, 2018 to 2030 (USD Million)
• 5.4. Diabetes Type 1
  • 5.4.1. Diabetes type 1 market, 2018 - 2030 (USD Million)
• 5.5. Diabetes Type 2
  • 5.5.1. Diabetes type 2 market, 2018 - 2030 (USD Million)

Chapter 6. Continuous Subcutaneous Insulin Infusion Market: End Use Business Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. End Use Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Hospitals & Clinics
  • 6.4.1. Hospitals & clinics market, 2018 - 2030 (USD Million)
• 6.5. Homecare
  • 6.5.1. Homecare market, 2018 - 2030 (USD Million)
• 6.6. Laboratories
  • 6.6.1. Laboratories market, 2018 - 2030 (USD Million)

Chapter 7. Continuous Subcutaneous Insulin Infusion Market: Regional Estimates & Trend Analysis by Product, Patient Type, and End Use

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamic
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive insights
    • 7.4.2.4. U.S. continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamic
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive insights
    • 7.4.3.4. Canada continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamic
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Competitive insights
    • 7.4.4.4. Mexico continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamic
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive insights
    • 7.5.2.4. UK continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamic
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive insights
    • 7.5.3.4. Germany continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamic
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive insights
    • 7.5.4.4. France continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamic
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive insights
    • 7.5.5.4. Italy continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamic
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive insights
    • 7.5.6.4. Spain continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key country dynamic
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Competitive insights
    • 7.5.7.4. Denmark continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamic
    • 7.5.8.2. Regulatory framework
    • 7.5.8.3. Competitive insights
    • 7.5.8.4. Sweden continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key country dynamic
    • 7.5.9.2. Regulatory framework
    • 7.5.9.3. Competitive insights
    • 7.5.9.4. Norway continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamic
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive insights
    • 7.6.2.4. Japan continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamic
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive insights
    • 7.6.3.4. China continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamic
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive insights
    • 7.6.4.4. India continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key country dynamic
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive insights
    • 7.6.5.4. Australia continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key country dynamic
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive insights
    • 7.6.6.4. South Korea continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamic
    • 7.6.7.2. Regulatory framework
    • 7.6.7.3. Competitive insights
    • 7.6.7.4. Thailand continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamic
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive insights
    • 7.7.2.4. Brazil continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamic
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive insights
    • 7.7.3.4. Argentina continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key country dynamic
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive insights
    • 7.8.2.4. South Africa continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key country dynamic
    • 7.8.3.2. Regulatory framework
    • 7.8.3.3. Competitive insights
    • 7.8.3.4. Saudi Arabia continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key country dynamic
    • 7.8.4.2. Regulatory framework
    • 7.8.4.3. Competitive insights
    • 7.8.4.4. UAE continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key country dynamic
    • 7.8.5.2. Regulatory framework
    • 7.8.5.3. Competitive insights
    • 7.8.5.4. Kuwait continuous subcutaneous insulin infusion market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Medtronic
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial performance
    • 8.5.1.3. Product benchmarking
    • 8.5.1.4. Strategic initiatives
  • 8.5.2. F. Hoffmann-La Roche Ltd
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial performance
    • 8.5.2.3. Product benchmarking
    • 8.5.2.4. Strategic initiatives
  • 8.5.3. ZEALAND PHARMA
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial performance
    • 8.5.3.3. Product benchmarking
    • 8.5.3.4. Strategic initiatives
  • 8.5.4. CeQur Simplicity
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial performance
    • 8.5.4.3. Product benchmarking
    • 8.5.4.4. Strategic initiatives
  • 8.5.5. Insulet Corporation
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial performance
    • 8.5.5.3. Product benchmarking
    • 8.5.5.4. Strategic initiatives
  • 8.5.6. YPSOMED
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial performance
    • 8.5.6.3. Product benchmarking
    • 8.5.6.4. Strategic initiatives
  • 8.5.7. B. Braun SE
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. BD (Becton, Dickinson and Company)
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product benchmarking
    • 8.5.8.4. Strategic initiatives